VA trial to weigh aspirin against other anti-clotting drugs in heart disease patients

December 10, 2000

For decades doctors have prescribed two drugs, aspirin and warfarin, to heart disease patients to help prevent blood clots, and although both drugs are effective they have never been compared in a large clinical trial. An international study begun recently by researchers at the San Francisco Veterans Affairs Medical Center (SFVAMC) will match these two old drugs against each other, and against a newer drug called clopidogrel, to see which of them prevents more heart attacks, strokes, and deaths in patients with chronic heart failure.

Unlike most international clinical trials in recent years, the 4,500-patient study will not be predominantly funded by a pharmaceutical or biotech company, said the study's chairman Barry Massie, MD, UCSF professor of medicine, and chief of the cardiology division at the SFVAMC. All three drugs in the trial already are approved for patients with heart disease and several other conditions. But the VA, which is paying about half of the trial's cost through its cooperative study program, recognized that determining which drug is most effective could save patient lives and might also reduce costs.

"The results of this study have the potential to greatly affect practice," Massie said. "For instance, between 20 and 40 percent of heart failure patients now receive warfarin. That figure will either increase or decrease substantially depending on the results. Aspirin is widely used in patients with coronary heart disease, the leading cause of heart failure. However, there is some evidence that aspirin may have negative effects in heart failure patients under some circumstances. If this proves to be so, many of these patients will be switched to warfarin or clopidogrel."

When the study is completed, Massie said, doctors will be able to choose among the three medicines based on three important factors: efficacy, safety and cost.

One of the most interesting and important questions the trial will address is whether aspirin interferes with a standard group of heart failure drugs known as ACE inhibitors, as some earlier studies have suggested.

"ACE inhibitors work by several mechanisms, one of which involves increasing the levels of chemicals called prostaglandins. Aspirin reduces the production of prostaglandins and therefore may interfere with part of the benefit of ACE inhibitors. This vitally important issue can only be addressed in a large controlled study such as WATCH (Warfarin and Antiplatelet Therapy in Chronic Heart failure), where aspirin is being compared to clopidogrel, another agent that prevents clotting and thrombosis by a mechanism that does not involve prostaglandins," Massie said.

Patients entering the so-called WATCH trial will be recruited from roughly 150 hospitals in the US, Canada and the United Kingdom. Each patient will be randomly assigned to take one of the three drugs for at least two years. Because each drug has been shown in separate studies to save lives, it would be unethical to assign a group to take a placebo, Massie said. The researchers will keep track of the number of heart attacks, strokes, deaths and bleeding incidents in each group.

The three drugs work by different mechanisms, and each has potential drawbacks. Warfarin, a blood thinner, prevents blood coagulation by interfering with vitamin K, which the body needs to make clotting proteins. It also can cause excessive bleeding, so patients require close monitoring and frequent blood tests. Aspirin and clopidogrel both work against platelets, blood cells that stick together and encourage clotting. Aspirin helps prevent platelets from clumping together. Clopidogrel prevents platelets from being activated, and while some studies show it works better than aspirin, it is also more expensive.

Aspirin and warfarin have never been directly compared in a clinical trial of heart failure patients, although both have been available for decades, Massie said. Warfarin's potential for preventing heart attacks in heart failure patients was only discovered a few years ago, he explained, and in the United States is usually not used for this application.

The San Francisco VA Medical Center will coordinate many aspects of the trial in conjunction with the Perry Point Maryland VA Cooperative Studies Coordinating Center, which will be conducted at approximately 40 VA Medical Centers, 50 non-VA hospitals in the US, and 60 sites in Canada and the UK. WATCH is the first VA-sponsored trial to coordinate with research sites overseas.
Among the researchers working on the project are national study coordinator Susan Ammon, RN, SFVAMC cardiology research nurse; John Teerlink, MD, UCSF assistant professor of cardiology and SFVAMC staff physician; Kelly Givner, SFVAMC administrative assistant. The data collection and analysis is being conducted at Perry Point under the direction of Joseph Collins, DSc, MD, and the statistician, William Krol , PhD. John Cleland, MD, professor of medicine at the University of Hull, UK; Koon Teo, MD, professor of medicine at McMaster University in London, Ontario; and Paul Armstrong, MD, professor of medicine at the University of Edmonton are lead investigators in the UK and Canada.

In addition to funding from the Department of Veterans Affairs, support for the study comes from Sanofi-Synthelabo, Bristol-Myers Squibb Company, and DuPont.

University of California - San Francisco

Related Heart Disease Articles from Brightsurf:

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

New 'atlas' of human heart cells first step toward precision treatments for heart disease
Scientists have for the first time documented all of the different cell types and genes expressed in the healthy human heart, in research published in the journal Nature.

With a heavy heart: How men and women develop heart disease differently
A new study by researchers from McGill University has uncovered that minerals causing aortic heart valve blockage in men and women are different, a discovery that could change how heart disease is diagnosed and treated.

Heart-healthy diets are naturally low in dietary cholesterol and can help to reduce the risk of heart disease and stroke
Eating a heart-healthy dietary pattern rich in vegetables, fruits, whole grains, low-fat dairy products, poultry, fish, legumes, vegetable oils and nuts, which is also limits salt, red and processed meats, refined-carbohydrates and added sugars, is relatively low in dietary cholesterol and supports healthy levels of artery-clogging LDL cholesterol.

Pacemakers can improve heart function in patients with chemotherapy-induced heart disease
Research has shown that treating chemotherapy-induced cardiomyopathy with commercially available cardiac resynchronization therapy (CRT) delivered through a surgically implanted defibrillator or pacemaker can significantly improve patient outcomes.

Arsenic in drinking water may change heart structure raising risk of heart disease
Drinking water that is contaminated with arsenic may lead to thickening of the heart's main pumping chamber in young adults, according to a new study by researchers at Columbia University Mailman School of Public Health.

New health calculator can help predict heart disease risk, estimate heart age
A new online health calculator can help people determine their risk of heart disease, as well as their heart age, accounting for sociodemographic factors such as ethnicity, sense of belonging and education, as well as health status and lifestyle behaviors.

Wide variation in rate of death between VA hospitals for patients with heart disease, heart failure
Death rates for veterans with ischemic heart disease and chronic heart failure varied widely across the Veterans Affairs (VA) health care system from 2010 to 2014, which could suggest differences in the quality of cardiovascular health care provided by VA medical centers.

Heart failure: The Alzheimer's disease of the heart?
Similar to how protein clumps build up in the brain in people with some neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, protein clumps appear to accumulate in the diseased hearts of mice and people with heart failure, according to a team led by Johns Hopkins University researchers.

Read More: Heart Disease News and Heart Disease Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to